TY - JOUR
T1 - Doxorubin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer
T2 - A preliminary report
AU - Logothetis, C. J.
AU - Von Eschenbach, A. C.
AU - Samuels, M. L.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1982
Y1 - 1982
N2 - Fifteen patients with advanced stage D hormone-resistant prostate cancer were treated with the combination of doxorubin, mitomycin, and 5-FU. Nine patients (60%) had objective responses, with a mean duration of 27.9 weeks. No responding patient has relapsed. Although three patients developed a culture-negative leukopenic fever, no deaths from chemotherapy occurred. Preliminary results with doxorubin, mitomycin, and 5-FU indicate that this is a very effective chemotherapy regimen, resulting in a high objective response rate in metastatic prostate cancer.
AB - Fifteen patients with advanced stage D hormone-resistant prostate cancer were treated with the combination of doxorubin, mitomycin, and 5-FU. Nine patients (60%) had objective responses, with a mean duration of 27.9 weeks. No responding patient has relapsed. Although three patients developed a culture-negative leukopenic fever, no deaths from chemotherapy occurred. Preliminary results with doxorubin, mitomycin, and 5-FU indicate that this is a very effective chemotherapy regimen, resulting in a high objective response rate in metastatic prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=0020003739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020003739&partnerID=8YFLogxK
M3 - Article
C2 - 7053267
AN - SCOPUS:0020003739
SN - 0361-5960
VL - 66
SP - 57
EP - 63
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 1
ER -